



USAN Council and INN Expert Committee suggests to rename burtomab to omburtamab

December 11, 2017

NEW YORK, December 11, 2017 – Y-mAbs Therapeutics, Inc. (YmAbs), an immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced that the USAN Council and INN Expert Committee has suggested to change the generic nonproprietary drug name of burtomab to omburtamab. YmAbs has accepted the suggestion.

About YmAbs:

YmAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer. We have a broad and clinically advanced product pipeline, including two late-stage and clinically validated product candidates, naxitamab and omburtamab, which target tumors that express ganglioside GD2 and B7-H3, respectively. Our mission is to become the world leader in developing better and safer antibody-based pediatric oncology products addressing clear unmet medical needs. We will expand into certain adult cancer indications and advance these in collaboration with our partners.

To learn more, visit www.ymabs.com.

SOURCE:

Y-mAbs Therapeutics, Inc.

Contact:

Ymabs Therapeutics, Inc.	YmAbs Therapeutics A/S
750 Third Avenue, 9th Floor	Rungsted Strandvej 113
New York, NY 10017	2960 Rungsted Kyst
USA	Denmark
+1 212 847 9844	+45 70 26 14 14
E-mail: info@ymabs.com	E-mail: info@ymabs.com